An Expert's Thoughts on the FDA Approval of Durvalumab in Locally Advanced Lung Cancers

Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer.

Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non—small cell lung cancer.

For over 20 years, experts have been searching for better treatment options for this patient population, Kris explains. However, some treatments have resulted in a decrease in survival through many attempts over the years.